BCAX vs COF · $1.51B cap vs P/E 62, rev $53.43B
Bicara Therapeutics Inc. Common Stock (BCAX) versus Capital One Financial Corporation (COF) — a side-by-side from cached financials, not a winner call.
Bicara Therapeutics Inc. Common Stock (BCAX) is a biotechnology company listed on NASDAQ.
Capital One Financial Corporation (COF) is a credit services company listed on NYSE.
BCAX does not have a complete income-statement cache yet.
Latest reported COF revenue for 2025-12-31 was $53.43B. Net income was $2.45B. Revenue was up 36.6% from 2024-12-31 to 2025-12-31. COF currently screens at market cap $125.00B and trailing P/E 61.8.
BCAX currently screens at market cap $1.51B. COF currently screens at market cap $125.00B and trailing P/E 61.8.
Not investment advice. Open the BCAX and COF stock pages for the full models.
Not investment advice.